Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.

AN Serafini, SJ Houston, I Resche, DP Quick… - Journal of Clinical …, 1998 - ascopubs.org
PURPOSE To evaluate the effectiveness and safety of samarium-153 (153Sm) lexidronam (EDTMP)
in a double-blind, placebo-controlled study. PATIENTS AND METHODS Patients …

[PDF][PDF] Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography

…, E Garin, S Rouquette, I Resche… - Journal of clinical …, 2006 - researchgate.net
… Caroline Rousseau, Anne Devillers, Christine Sagan, Ludovic Ferrer, Boumédiène Bridji,
Loıc Campion, Myriam Ricaud, Emmanuelle Bourbouloux, Isabelle Doutriaux, Martine …

Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement

…, C Rousseau, S Bourdin, JF Chatal, I Resche - European journal of …, 2000 - Springer
This retrospective study evaluated the toxicity and efficacy of strontium-89 chloride (Metastron,
Amersham) in 94 patients with painful bone metastases of prostate cancer (117 injections …

Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma

E Mirallié, T Guillan, B Bridji, I Resche, C Rousseau… - Surgery, 2007 - Elsevier
BACKGROUND: 18-F-fluoro-2-deoxyglucose positron emission tomography ( 18 FDG-PET)
is useful in the detection of iodine-negative differentiated thyroid carcinoma (DTC). The aim …

Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial

…, A Murat, TC Ferreira, M Bardiès, L Ferrer, I Resche… - Clinical cancer …, 1999 - AACR
The toxicity and therapeutic efficacy of escalating doses of anti-carcinoembryonic antigen ×
anti-Nα-(diethylenetriamine-N,N,N′,N″-tetraacetic acid)-In bispecific monoclonal antibody (…

Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma

…, C Sagan, C Ansquer, A Testard, I Resche… - European journal of …, 2010 - Springer
Purpose The aim of this retrospective study was to evaluate the contribution of 18 F-FDG
PET to the clinical management and survival outcome of patients suspected of recurrent …

Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen× anti-hapten bispecific antibody-mediated pretargeting of iodine-131 …

…, JP Vuillez, PY Brard, C Rousseau, I Resche… - Clinical cancer …, 2003 - AACR
Purpose: Pharmacokinetics and dosimetry of hMN-14 × m734 bispecific monoclonal
antibody (BsMAb) and 131 I-labeled di-diethylenetriaminepentaacetic acid-indium ( 131 I-hapten) …

Prospective comparison of 3 γ-probes for sentinel lymph node detection in 200 breast cancer patients

…, A Lisbona, L Ferrer, L Campion, I Resche… - Journal of Nuclear …, 2005 - Soc Nuclear Med
Previous reports have shown that axillary sentinel lymph node (ASLN) radiodetection allows
accurate axillary staging for patients with early breast cancer. Radioguided surgery implies …

Validation of axillary sentinel lymph node detection in the staging of early lobular invasive breast carcinoma: a prospective study

…, C Curtet, F Dravet, R Pioud, C Rousseau, I Resche… - Cancer, 2004 - Wiley Online Library
BACKGROUND Previous reports have shown that regional lymph node involvement in
patients with early‐stage breast carcinoma can be evaluated by resection of axillary sentinel …

Impact of PET-FDG in the diagnosis and therapeutic care of patients presenting with metastases of unknown primary

…, C Bouriel, AM Bernard, B Bridji, I Resche - Cancer …, 2007 - Taylor & Francis
We carried out a study to evaluate the contribution of positron emission tomography with 18
F-fluorodeoxyglucose (PET-FDG) in the diagnosis and therapeutic care of patients …